FDAnews Drug Daily Bulletin

DNAPRINT GENOMICS' BUSINESS PARTNER BIOFRONTERA AG COMPLETES 20 MILLION EURO BOND PLACEMENT

Sept. 7, 2005
A A

DNAPrint(tm) genomics, Inc. (OTCBB:DNAG), which holds an 18% stake in German pharmaceutical company Biofrontera AG, today announced that Biofrontera has completed a 20 million euro bond placement. The bonds began trading on the Frankfurt exchange on Wednesday, August 31, under the symbol (ISIN DE 000 A0E 964 9). If Biofrontera completes a public offering in the future, each purchaser in the offering at 100 euros can convert to 6.2 shares of Biofrontera stock. This conversion rate attributes a price of 16.13 euros per share to the Biofrontera common shares.

ArriveNet

(http://press.arrivenet.com/bus/article.php/688901.html)